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Small ubiquitin-related modifier (SUMO) is impli-
cated in the regulation of numerous biological
processes including transcription, protein localiza-
tion, and cell cycle control. Protein modification by
SUMO is found in Plasmodium falciparum; however,
its role in the regulation of the parasite life cycle is
poorly understood. Here we describe functional
studies of a SUMO-specific protease (SENP) of
P. falciparum, PfSENP1 (PFL1635w). Expression of
the catalytic domain of PfSENP1 and biochemical
profiling using a positional scanning substrate library
demonstrated that this protease has unique
cleavage sequence preference relative to the human
SENPs. In addition, we describe a class of small
molecule inhibitors of this protease. The most potent
lead compound inhibited both recombinant PfSENP1
activity and P. falciparum replication in infected
human blood. These studies provide valuable new
tools for the study of SUMOylation in P. falciparum.
INTRODUCTION
Small ubiquitin-related modifier (SUMO) is a posttranslational
modifier in eukaryotes that is structurally related to ubiquitin yet
functionally distinct. SUMO modification has been implicated in
the regulation of numerous biological processes including tran-
scription (Desterro et al., 1998), protein localization (Matunis
et al., 1996), and cell cycle control (Ulrich, 2009). Like other
reversible posttranslational modifications (i.e., ubiquitination,
acetylation, methylation and phosphorylation), SUMOylation is
highly dynamicwith diverse and complex functional implications.
SUMOylated proteins were recently identified in Plasmodium
falciparum, a unicellular eukaryotic parasite that causes human
malaria (Issar et al., 2008), suggesting that SUMOylation may
play similarly important roles in parasite growth and survival.Chemistry & Biology 18,P. falciparum is the causative agent of human malaria, infect-
ing 250 million people per year and causing nearly 800,000
deaths (Aregawi et al., 2008). The parasite has a complex and
highly regulated life cycle in both the human andmosquito hosts.
Numerous transcriptional and proteomic profiling studies have
demonstrated that patterns of gene and protein expression are
highly regulated during the blood stage life cycle (Bozdech
et al., 2003; Khan et al., 2005; Le Roch et al., 2003).
P. falciparum lacks canonical eukaryotic transcription factors,
but novel transcription factors and epigenetic and posttranscrip-
tional regulatory factors have recently been identified (Painter
et al., 2011). Beyond regulation at the transcriptional level,
multiple unexpected protein isoforms in proteomic analyses
suggest that posttranscriptional and posttranslational modifica-
tions may play important and unique roles in the regulation of
parasite survival inside the host (Coulson et al., 2004; Foth
et al., 2008; Shock et al., 2007). Thus, SUMOylation may
represent one of several key mechanisms that the parasite
uses to control gene expression profiles. Proteomic analysis of
SUMOylated proteins from both P. falciparum and Toxoplasma
gondii, demonstrated that proteins from numerous essential bio-
logical pathways, including proteins that are unique to these
parasites, are modified by SUMO (Braun et al., 2009; Issar
et al., 2008). In P. falciparum, PfSir2, an epigenetic regulator of
parasite antigenic variation, is modified by SUMO (Issar et al.,
2008). Although a preliminary list of SUMO modified proteins
has been generated, the importance of SUMO modification
and its regulatory machinery in P. falciparum remains unclear.
SUMOylation of target proteins is regulated by dedicated
enzymatic machinery, including a family of SUMO-specific
proteases (SENPs) (Yeh, 2009). SENPs play two primary roles
in SUMO regulation: they process SUMO precursors to reveal
a C-terminal di-glycine before conjugation, and they cleave the
isopeptide bond between the C-terminal glycine of SUMO and
the lysine side chain of a target protein. Bioinformatic analysis
has predicted two P. falciparum SENPs (Issar et al., 2008;
Ponder and Bogyo, 2007; Wu et al., 2003). However, functional
studies of the P. falciparum SENPs have posed many chal-
lenges. Traditional genetic disruption of P. falciparum SENPs
will likely not be possible given the essential role of SENPs in711–721, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 711
Figure 1. Plasmodium falciparum Has Two Predicted Sumo-Specific Proteases
(A) ClustalW alignment of the catalytic residues of six human SENPs, two yeast SENPs, and the two predicted SENPs from P. falciparum, Plasmodium berghei,
and Plasmodium yoelii. Completely conserved identical residues are blocked in blue, conserved identical residues in green, and conserved similar residues in
yellow. Aligned catalytic residues are denoted by the red (*).
(B) Phylogram depicting the relationship between the human, yeast, and Plasmodium sp. SENP catalytic domains. The bootstrap number is shown for each node.
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Knockdown of gene expression by RNAi is not possible in
P. falciparum, and, although two promising conditional gene
knockout systems have been developed, the inherent leakiness
of both systems limits their applications (Armstrong and Gold-
berg, 2007; Baum et al., 2009; Meissner et al., 2005). As an alter-
native to genetic disruption, small molecule inhibitors have been
successfully used to characterize the function of several
P. falciparum proteases (Arastu-Kapur et al., 2008; Yeoh et al.,
2007). However, there are currently no small molecule inhibitors
that target SENPs from any organism.
To understand the dynamics of SUMOylation in P. falciparum,
we aimed to characterize the predicted SENPs and to identify
small molecule inhibitors that perturb their function. In this study,
we identified two putative SENPs of P. falciparum using bio-
informatics analyses: PfSENP1 (PFL1635w) and PfSENP2
(MAL8P1.157).Wewere able to recombinantly express PfSENP1
and determine that it has robust SUMO processing activity and
a unique cleavage site preference relative to the human SENPs.
Using a SUMO processing assay, we screened a library of irre-
versible cysteine protease inhibitors and identified a single
compound, JCP-666, that inhibits PfSUMO processing both by712 Chemistry & Biology 18, 711–721, June 24, 2011 ª2011 Elsevierparasite lysates and by recombinant PfSENP1 and also blocked
parasite replication in human blood. We subsequently synthe-
sized a more potent analog, VEA-260, with improved stability.
Together, our data suggest that PfSENP1 activity is essential
for parasite growth, and that the novel inhibitor scaffold identified
here may be useful for the development of inhibitors of PfSENP1
that do not inhibit SENPs of the human host.
RESULTS
P. falciparum Has Two Putative SENPs
A search of the P. falciparum genome using sequence homology
identified two genes encoding putative SENPs: PFL1635w and
MAL8P1.157 (Ponder and Bogyo, 2007; Wu et al., 2003). Align-
ment of the catalytic domain of these proteins with the human
and yeast SENPs suggested that the essential catalytic residues
are conserved (Figure 1A). The catalytic domain of PFL1635w,
which we refer to as PfSENP1, is more closely related to the
human SENPs whereas MAL8P1.157, referred to as PfSENP2,
is divergent and found within a branch that is only loosely related
to the yeast Ulp1 and highly related to a similar sequence in other
Plasmodium species (Figure 1B). Analysis of microarray dataLtd All rights reserved
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are expressed during the intraerythrocytic life cycle with peak
expression in the late trophozoite phase (25 hr postinvasion),
and lowest expression in the early ring stage, immediately after
invasion (Bozdech et al., 2003; Le Roch et al., 2003).
Lysates ofP. falciparumHave SUMOProcessing Activity
Although the predicted SENP mRNAs appear to be transcribed
in P. falciparum, it is unclear if the resulting proteins are ex-
pressed or catalytically active. One function of the previously
characterized SENPs in higher eukaryotes is to prepare SUMO
for conjugation by proteolytically removing the C-terminal amino
acids from the precursor SUMO protein (SUMO-pro) to reveal
a C-terminal di-glycine motif. By adding a His6-tag after the
C-terminal extension of SUMO-pro, processing can be moni-
tored by gel shift assay (Mikolajczyk et al., 2007). Using this
assay we found that P. falciparum lysates efficiently processed
SUMO-pro (PfSUMO-pro) (Figure 2A). Furthermore, this pro-
cessing activity could be blocked by preincubation of parasite
lysates with either N-ethylmaleimide (NEM) or human SUMO
protein modified with a vinyl sulfone reactive group after the
C-terminal di-glycine (hSUMO-VS). NEM blocks SENP activity
by acting as a general alkylating agent that modifies the active
site cysteine, whereas hSUMO-VS is an irreversible inhibitor of
SENP proteases that contains the full length SUMO protein
fused to a reactive vinyl sulfone group (Borodovsky et al.,
2001). Inhibition by these agents suggests that the PfSUMO-
pro processing observed in parasite lysates is the result of active
PfSENPs.
P. falciparum development in the red blood cell is highly regu-
lated, with many genes and proteins varying in expression and
activity over the course of replication (Bozdech et al., 2003; Le
Roch et al., 2003). To determine when PfSENPs are active during
the parasite blood stage life cycle, we harvested synchronous
cultures of P. falciparum every 8 hr for 48 hr starting at 14 hr
postinvasion. Incubation of lysates with PfSUMO-pro resulted
in a peak in protease activity at 30 hr postinvasion, correspond-
ing to the late trophozoite stage. Processing activity was lowest
during the ring stage (14 and 48 hr postinvasion) (Figure 2B; see
Figure S1 available online), in agreement with the gene expres-
sion patterns of both of the predicted SENPs (Bozdech et al.,
2003; Le Roch et al., 2003).
To assess the specificity of the SUMO processing activity in
parasite lysates, we monitored processing of multiple related
human SUMO sequences (hSUMO-1-pro, hSUMO-2-pro, or
hSUMO-3-pro). Recombinantly expressed human SENP1
protease (hSENP1) processed both PfSUMO-pro and all three
human SUMOs. P. falciparum lysates, on the other hand, pro-
cessed PfSUMO-pro and hSUMO-1-pro but not hSUMO-2-pro
or hSUMO-3-pro (Figure 2C). Thus, the parasite enzyme differs
from the human enzyme in its specificity toward its substrate.
Because recent studies have demonstrated that processing of
SUMO-pro by SENPs is sensitive to the sequence of the
C-terminal amino acid extension after the di-glycine (Mikolajczyk
et al., 2007), we wanted to determine if specific sequence differ-
ences in the C-terminal extensions of the SUMOs could explain
the substrate specificity observed in parasite lysates. We gener-
ated chimeric SUMOs by swapping the C-terminal amino acid
tails to create PfSUMO-h2pro, PfSUMO-h3pro, and hSUMO2-Chemistry & Biology 18,Pfpro. Whereas P. falciparum lysates failed to cleave chimeric
PfSUMO-h2pro and -h3pro, chimeric hSUMO2-Pfpro was
cleaved by parasite lysates (Figure 2D). Therefore, differences
in C-terminal amino acid sequences rather than differences in
the core SUMO sequence impact substrate recognition by para-
site SENPs.
Expression and Characterization of PfSENP1 and 2
Although these results confirmed SENP activity in P. falciparum
extracts, it was not clear if PfSENP1 and/or PfSENP2 were
responsible for this activity. Therefore, we attempted to
express the catalytic domains of both PfSENP1 and PfSENP2
in Escherichia coli. Despite multiple attempts, we could only
express and purify the catalytic domain of PfSENP1. The result-
ing recombinant PfSENP1 efficiently cleaved PfSUMO-pro, and
cleavage was inhibited by both NEM pretreatment and by muta-
tion of the predicted catalytic cysteine to alanine (Figure 3A). In
addition, we found that recombinant wild-type but not the cata-
lytically deadmutant PfSENP1 cleaved hSUMO-1 from the lysine
side chain of RanGAP1, a well-characterized SUMO-modified
protein (Figure 3B).
PfSENP2 homologs (yeast Ulp2 and hSENP6 and 7) primarily
function in the processing of poly-SUMO chains (Kroetz et al.,
2009; Lima and Reverter, 2008), on hSUMO-2, -3, and yeast
SUMO (SMT3) at canonical SUMOylation motif sites.
However, P. falciparum SUMO, like hSUMO-1, lacks canonical
SUMOylation sites (Figure S2), suggesting that the parasite
does not poly-SUMOylate substrates. To determine if PfSUMO
can itself be SUMOylated, we used a previously described
system (Uchimura et al., 2004) in which E. coli is cotransformed
with a tricistronic plasmid for the overexpression of the
SUMOylation machinery. Expression of the human SUMOylation
proteins resulted in the formation of poly-SUMO chains that
could be enriched using the C-terminal His6 tag on the unpro-
cessed hSUMO-2 (Figure 3C). In contrast, cotransformation
with PfSUMO-pro resulted in the recovery of only unprocessed
PfSUMO (Figure 3C). These data suggest that PfSUMO cannot
be SUMOylated and therefore cannot form poly-SUMO chains
in the parasite. Given the lack of poly-SUMOylation and our
inability to express recombinant PfSENP2, it is unclear what
role, if any, PfSENP2 plays in the regulation of SUMO in
P. falciparum.
PfSENP1 Has Unique Substrate Sequence Specificity
The SUMO regulatory machinery of P. falciparum differs from its
human host in that P. falciparum has only two predicted SENP
proteases whereas humans have six SENPs. Differences in the
ability of parasite lysates to cleave a panel of human SUMOs
suggested that PfSENP1 might be biochemically distinct from
the SENPs of its human host. We therefore analyzed the
cleavage site specificity of PfSENP1 using a positional scanning
substrate library. This library was previously used to characterize
the preferred amino acid cleavage sequences of five human
SENP proteases, hSENP8, and three human de-ubiquitinating
proteases (DUBs), a distinct class of proteases that can cleave
after the C-terminal diglycine of ubiquitin (Drag et al., 2008a,
2008b). Specifically, we used the P2, P3, and P4 positional scan-
ning libraries to compare the specificity profiles of PfSENP1 to
the human SENPs (Figure 3D). Not surprisingly, PfSENP1 only711–721, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 713
Figure 2. Plasmodium falciparum Lysates Have SENP activity
(A) SENP activity in P. falciparum lysates. The soluble fraction of mixed stage parasite lysates (3D7 lysate) was incubated with or without N-ethylmaleimide
(NEM; 10 mM) or hSUMO-VS (10 mM) followed by PfSUMO-pro. Cleavage reactions were resolved by SDS-PAGE and visualized with Gelcode blue protein stain.
PfSUMO-pro alone and recombinant human SENP1 (hSENP1)-cleaved PfSUMO-pro were included as negative and positive controls for cleavage, respectively.
(B) SENP activity throughout intra-erythrocytic life cycle. Synchronous blood stage cultures of P. falciparum were harvested every 8 hr for 48 hr, lysed by
hypotonic lysis, and normalized for protein content (excluding hemoglobin). Equal protein concentrations from each time point were incubatedwith PfSUMO-pro,
resolved by SDS-PAGE, visualized by Gelcode Blue, and the percent cleavage was quantified by ImageJ analysis. Bars represent average percent cleavage for
each time point and error bars denote standard deviation (n = 3).
(C) Cleavage of SUMO-pro panel. Mixed stage parasite lysates, with or without hSUMO-VS pretreatment, or hSENP1 were incubated with SUMO-pro from
P. falciparum (PfSUMO) or humans (hSUMO-1, -2, -3). Cleavage reactions were resolved and visualized as described above. The C-terminal amino acid
sequence that is processed after the diglycine by SENPs is denoted in the detached boxes.
(D) Cleavage of chimeric SUMO-pro. Chimeric SUMO-pro proteins, as depicted on the left, were incubated with mixed stage parasite lysates, with or without
hSUMO-VS preincubation, or hSENP1 and visualized as described above.
See also Figure S1.
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Figure 3. In Vitro Biochemical Characterization of PfSENP1 and
Poly-SUMOylation
(A) PfSUMO-pro cleavage by PfSENP1. PfSUMO-pro was incubated with no
enzyme, PfSENP1 (WT), PfSENP1 pretreated with 10 mM N-ethylmaleimide
(WT+NEM), or PfSENP1 catalytic mutant (C984A). Cleavage reactions were
resolved by SDS-PAGE and visualized with Gelcode Blue protein stain
reagent.
(B) Cleavage of SUMO from a target protein by PfSENP1. hSUMO-1 modified
Flag-RanGAP was incubated with PfSENP1 or PfSENP1 C984A. Cleavage
reactions were resolved by SDS-PAGE and visualized by western blot using an
anti-Flag antibody.
(C) E. coli were cotransformed with pT-E1/E2S2 and either pET28a-hSUMO2-
pro-His6 or pET29a-PfSUMO-pro-His6. After induction, proteins were en-
richedwith Ni2+-NTA, and eluted with imidazole. Eluted proteins were resolved
by SDS-PAGE and visualized by Gelcode Blue protein stain reagent.
(D) PfSENP1 (0.5 uM) was incubated with the indicated positional scanning
substrate library, and ACC production was measured in triplicate using
a fluorescence plate reader. Activity relative to the best amino acid was
determined. A heat map of these data as well as published data on hSENPs 1-
2, 5-8, and four human deubiquitinating enzymes, UCH-L3, Iso-T, OTU-1 and
Plpro, is shown. Red indicates 100% cleavage activity and white indicates 0%
cleavage activity.
See also Figure S2 and Figure S3.
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Chemistry & Biology 18,tolerated glycine in the P2 position. In the P3 position, PfSENP1,
like hSENP1 and hSENP2, tolerated awide range of amino acids.
In the P4 position, PfSENP1 showed the greatest preference for
glutamine, leucine, and norleucine. Glutamine is the native P4
amino acid of P. falciparum SUMO and all three human SUMOs;
it also is the preferred P4 amino acid of hSENP1, 2, and 5.
Leucine is the native P4 position of ubiquitin and is therefore
strongly preferred in this position for DUBs. Among the human
SENPs, only hSENP6, 7, and 8 preferentially cleave leucine
over glutamine in the P4 position. Our findings also demonstrate
that PfSENP1 shares P4 specificity with both groups of human
SENPs but also accepts several additional amino acids in the
P4 position that are not well tolerated by the hSENPs, including
arginine, isoleucine, and threonine.
To determine if differences observed in peptide substrate
specificity translate into differences in specificity in the context
of the native SUMO substrate, we mutated glutamine 95
(the equivalent of the substrate P4 position) of PfSUMO-pro to
threonine (PfSUMOQ95T-pro). The PfSUMOQ95T-pro mutation
resulted in a 2-fold decrease in substrate processing by
PfSENP1 relative to the wild-type PfSUMO-pro substrate (Fig-
ure S3A). In contrast, hSENP1 processing of PfSUMOQ95T-
pro was decreased by >25-fold relative to processing of the
wild-type PfSUMO-pro (Figure S3B). These data suggest that
the P4 position could be used to drive selectivity away from
the closest human homologs of PfSENP1, namely hSENP1 and 2.
Identification of PfSENP1 Inhibitors
The only reported SENP inhibitors are general cysteine alkylating
agents and the full-length SUMOprotein modified with a reactive
group, such as a vinyl sulfone (Borodovsky et al., 2002). Although
effective for some biochemical assays, these inhibitors cannot
be used to study SENPs in live cells. In addition, biotinylated
probes consisting of 5–13 amino acids from the C terminus of
SUMOmodified with a vinyl sulfone reactive group have been re-
ported as probes of SENP proteases (Borodovsky et al., 2005).
However, these probes have not been shown to have SENP
inhibitory activity. Therefore, we decided to screen a highly
focused library of 508 irreversible cysteine proteases inhibitors
(Arastu-Kapur et al., 2008) using the parasite lysate PfSUMO-
pro processing assay to identify novel small molecule SENP
inhibitors (Figure S4). This library was used previously in
P. falciparum to identify novel inhibitors of host cell rupture and
includes general scaffolds of covalent irreversible cysteine
protease inhibitors (Arastu-Kapur et al., 2008). Because we
were unable to express PfSENP2, we screened the inhibitor
library against the native SUMO processing activity in parasite
lysates rather than recombinant PfSENP1 alone. Interestingly,
of the 508 compounds screened, only one inhibitor, JCP-666,
reproducibly blocked SUMO-pro processing (Figure 4A).
JCP-666 contains an aza-epoxide reactive group with a P1 as-
partic acid side chain. Unlike the majority of aza-epoxide-based
inhibitors in the library, JCP-666 lacks a P2 amino acid side
chain. Chemical characterization of the compound indicated
the primary species in the library was a mixture of chlorohydrin
forms of the ring opened epoxide that formed during synthesis
as a result of the removal of a BOC group with HCl (Figure 4B;
Supplemental Compound Synthesis). Because we could not
isolate the epoxide form of JCP-666, we used the mixture of711–721, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 715
Figure 4. Screening and Identification of a Novel PfSENP Inhibitor
(A) Structure of JCP-666.
(B) Structure of chlorohydrin isomers of JCP-666.
(C) Structure of VEA-260.
(D) VEA-260 inhibits PfSENP1. Purified recombinant PfSENP1 (100 nM) was incubated with VEA-260 (0–200 mM) followed by cleavage of PfSUMO-pro and
assessed as described above.
(E) Soluble mixed stage P. falciparum lysates were pretreated with VEA-260 (0–200 mM) followed by cleavage of PfSUMO-pro. PfSUMO-pro without lysate added
was included as a control in lane C. Samples were separated by SDS-PAGE and visualized as described above.
(F) VEA-260 irreversibly inhibits PfSENP1. PfSENP1 was treated with VEA-260 (200 mM), NEM (10mM), or DMSO. Input samples were taken. The inhibitor treated
protease was diluted, enriched with Ni-NTA, and eluted with imidazole. Input (I) and elution (E) samples were added to PfSUMO-pro and cleavage visualized as
described above.
(G) Total mixed stage P. falciparum lysates were pretreated with VEA-260 (0–250 mM) or DCG-04 (100 mM; lane C), a falcipain inhibitor, followed by labeling with
125I labeled DCG-04. Proteins were separated by SDS-PAGE and visualized by autoradiography.
See also Figure S4 and Figure S5.
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to these simply at JCP-666. We did not find any evidence of
similar chlorohydrin species for the related analogs JCP-665,
JCP-667, JCP-668 even though these compounds were
prepared using the same synthesis methods (Scheme S1). Inter-
estingly, both the epoxide and chlorohydrin forms of JCP-666716 Chemistry & Biology 18, 711–721, June 24, 2011 ª2011 Elsevierwere able to inhibit PfSENP1 activity (Figures S5). This suggests
that either the chlorohydrin isomers interconvert to the epoxide
in reaction buffer or the chlorohydrin forms are also active as
inhibitors (Scheme S2). Thus, the chlorohydrin form of
JCP-666 may inhibit the target SENP by SN2-like displacement
of the chloride by the active site cysteine. This is consistentLtd All rights reserved
Table 1. Inhibition of SENP and DUB Fluorogenic Substrate Cleavage by JCP-666 and VEA-260
Protease Substrate JCP-666 (1b) IC50 (mM) VEA-260 IC50 (mM)
PfSENP1 QTGG-AFC 17.9 ± 1.0 16.2 ± 1.5
hSENP1 QTGG-AFC 9.0 ± 0.5 7.1 ± 0.6
hSENP2 QTGG-AFC 4.7 ± 0.5 3.7 ± 0.2
hSENP6 LRGG-AFC >100 >100
hSENP8 (deNEDDylase) LRGG-AFC >100 9.1 ± 1.2
IsoT (USP5) LRGG-AFC >100 ND
UCH-L3 LRGG-AFC >100 100
ND, not determined.
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inhibited PfSENP1. In addition, the chlorohydrins also inhibited
human SENP1 activity against SUMO-pro and also the
SUMOylated RanGAP substrate (Figure S5). Regardless, the
overall instability of the JCP-666 epoxide and the presence of
multiple isomers of the chlorohydrin prompted us to develop
an alternative inhibitor for use in all subsequent studies.
For our first analog of JCP-666, we removed the aspartic acid
side chain on the main aza-epoxide scaffold. We reasoned that
changes in this region would likely alter the stability of the
epoxide group. Furthermore, removal of this group would
simplify the synthesis by reducing steric hindrance for the key
coupling reaction between the peptide scaffold and the epoxide
of the molecule. We therefore synthesized VEA-260, which is
identical to JCP-666 but lacks the P1 aspartic acid side chain
(Figure 4C). This new analog was as potent as the original
JCP-666 against both recombinant PfSENP1 (Figure 4D; Fig-
ure S5A) and PfSENP activity in parasite lysates (Figure 4E and
Figure S5B) suggesting that this aspartic acid side chain is not
essential for binding to the target enzyme. Furthermore,
VEA-260, like JCP-666, acted as an irreversible inhibitor of
PfSENP (Figure 4F; Figure S5C). Importantly, VEA-260 was not
susceptible to epoxide ring opening during synthesis and could
be isolated in the epoxide form.
To assess the selectivity of VEA-260 for P. falciparum SENPs,
we examined whether it inhibited other P. falciparum
cysteine proteases. Specifically, we incubated mixed-stage
P. falciparum lysates with various concentrations of VEA-260
and measured the residual activity of falcipains 1/2/3 using
radiolabeled probes as described previously (Arastu-Kapur
et al., 2008; Greenbaum et al., 2002). Importantly, VEA-260,
like JCP-666 (Figures S5D and S5E) did not inhibit any of the
falcipains (Figure 4G), suggesting that it is likely to be sufficiently
selective to allow its use for studies in live parasite cultures.
To assess whether VEA-260 was selective for parasite SENP
activity over other SENP proteases and the related deubiquiti-
nating proteases (DUBs), we monitored inhibition using the
QTGG-AFC and LRGG-AFC fluorogenic substrates previously
optimized for these proteases (Table 1) (Drag et al., 2008a,
2008b). PfSENP1 and its closest human homologs (hSENP1
and 2) were all potently inhibited by VEA-260 and JCP-666. In
contrast, hSENP6 (a homolog of PfSENP2) and UCH-L3
(a DUB) were not inhibited by VEA-260. Human SENP8 (a de-
NEDDylase) was inhibited by VEA-260 (Albrow et al., 2011) but
not JCP-666, suggesting that removal of the aspartic acid P1Chemistry & Biology 18,side chain may reduce selectivity to some extent. However,
neither P. falciparum nor human red blood cells express
hSENP8.
VEA-260 Inhibits P. falciparum Replication
To determine the effects of inhibition of PfSENP activity on
P. falciparum growth, we used VEA-260 for phenotypic studies
in parasites cultured in human red blood cells. Although only
JCP-666 was identified from the library screen, a further search
of the library identified three additional compounds (JCP-665,
667, and 668) that are highly related in structure to VEA-260
and JCP-666 (Figure 5A). All three analogs have the aspartic
acid P1 side chain like JCP-666. JCP-665 and JCP-667 further
differ from VEA-260 only in the size of the aromatic groups on
the terminal amide, whereas JCP-668 differs from VEA-260 in
the reactive electrophile group. Interestingly, none of these
analogs were obtained as the chlorohydrin form even though
they were originally synthesized using the same chemistries.
This suggests that the combination of the large di-naphthyl
groups and the P1 aspartic acid side chain cause the reduced
stability of the epoxide of JCP-666 to HCl. All three analogs in
the library did not inhibit PfSUMO-pro processing in
P. falciparum lysates at the concentration originally used in our
screen. However, we evaluated their ability to inhibit PfSENP1
at higher concentrations and found that JCP-668 also has
weak activity (Figure 5A). The lower potency of JCP-668
suggests that the reactive electrophile affects potency, whereas
the reduced potency of JCP-665 and JCP-667 suggest that
bulky aromatics are required for efficient binding to PfSENP1.
Treatment of synchronous ring stage cultures with VEA-260,
JCP-665, JCP-667, and JCP-668 demonstrated that VEA-260
most potently inhibits parasite replication (EC50 70 ± 20 mM)
followed by JCP-668 (EC50 220 ± 30 mM; Figure 5B). JCP-667
had no effect that could be measured within the solubility range
of the compound. Interestingly, JCP-665 showed a shallow cell
killing curve but was unable to affect complete clearance of
the parasites (EC50 could not be determined). This non-dose-
dependent activity for JCP-665 may result from general toxicity
of the compound. Regardless, these data confirm that potency
against PfSENP1 correlates with parasite killing, suggesting
that PfSENP1 is likely to be an essential protease.
Finally, to more carefully monitor the effects of VEA-260 on
parasite growth, we treated synchronously grown cultures of in-
fected RBCs with 100 mM concentrations of the drug at various
points in the blood stage life cycle. We then analyzed thin blood711–721, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 717
Figure 5. VEA-260 Inhibits Parasite Replication and Blocks Rupture When Added at Schizont Stage
(A) PfSENP1 was pretreated with JCP-665, -667, or -668 (0–300 mM) followed by addition of PfSUMO-pro. Cleavage reactions were resolved by SDS-PAGE and
visualized by Gelcode Blue protein stain reagent. PfSUMO-pro without protease was included as a control (lane C).
(B) Synchronous ring-stage P. falciparum cultures were treated with indicated inhibitor (0–300 mM) and incubated for 75 hr. Cultures were then fixed, per-
meabilized, and stained with propidium iodide. Parasitemia was quantified by flow cytometry, and the parasitemia relative to DMSO treated controls was
determined. The parasitemia relative to DMSO ± SD is shown for each concentration.
(C) Images of Giemsa-stained thin blood smears from synchronously grown parasite cultures treated with 100 mM VEA-260 at the indicated life cycle stage
compared to a DMSO control. Smears were taken at the indicated times after addition of the compound.
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Functional Studies of PfSENP1smears of the parasites 12 hr later (Figure 5C). These results indi-
cate that only parasites treated at the late schizont stage (i.e.,
3 hr before rupture from the host [3 hr]) looked morphologically
altered and unable to release from the host RBC. The fact that
parasites treated at earlier life cycle stages did not show any
significant change in growth progression or cell morphology
confirms that the compound is not generally toxic to the para-
sites. It also suggests that blocking deSUMOylation of proteins
may be most detrimental for the parasite as it prepares to exit
the host cell. Further studies into the reason for this stage
specific effect of the inhibitor are currently ongoing.
DISCUSSION
SENPs play an essential role in the regulation of SUMOylation,
a posttranslational modification that modulates numerous
biological processes. The essential role of SENPs in other
eukaryotes suggests these proteases may also be essential
for P. falciparum. In this study, we demonstrated that
P. falciparum has at least one active SENP protease, PfSENP1.
Using a positional scanning substrate library, we demonstrated
that PfSENP1 has distinct cleavage specificity relative to its718 Chemistry & Biology 18, 711–721, June 24, 2011 ª2011 Elsevierhuman homologs. By screening a library of cysteine protease
inhibitors we identified one compound, JCP-666, that inhibited
SUMO processing by parasite lysates and recombinant
PfSENP1. Because of the instability in the epoxide electrophile
of JCP-666, we focused our efforts on a novel analog VEA-260
that showed increased potency and overall stability compared
to JCP-666. This compound inhibited parasite replication in
a dose-dependent manner, suggesting that PfSENP activity is
essential for parasite survival.
The ability of VEA-260 to inhibit PfSUMO processing by both
recombinant PfSENP1 and soluble parasite lysates, the selec-
tivity of VEA-260 for hSENP1/2-like proteases over PfSENP2
human homologs, and the ability of VEA-260 to block parasite
replication all suggest that PfSENP1 is the major SENP protease
in P. falciparum lysates. Although the precise effect of VEA-260
on PfSENP2 is unknown, these data suggest one of three
possible scenarios: VEA-260 inhibits both PfSENP1 and 2, inhi-
bition of PfSENP1 alone is sufficient to block parasite replication,
or PfSENP2 is not an active protease. P. falciparum, like yeast,
has only two predicted SENP proteases. PfSENP1 is more
closely related to yeast Ulp1 (hSENP1/2-like) and PfSENP2 is
more closely related to yeast Ulp2 (hSENP6/7-like). Ulp1 isLtd All rights reserved
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hSENP1/2 that are susceptible to VEA-260 inhibition. In contrast,
Ulp2 is localized to the nucleus and can be genetically disrupted
(Kroetz et al., 2009; Li andHochstrasser, 2003). Defects resulting
from Ulp2 disruption can be partially overcome by overexpres-
sion of the catalytic domain of Ulp1. Ulp2 is more closely related
to the subset of human SENPs that includes hSENP6 and 7. As
demonstrated here, VEA-260 is not an effective inhibitor of
hSENP6, suggesting PfSENP2 is a less likely to be a target of
this inhibitor. Therefore, we propose that PfSENP1 is the primary
protease responsible for the SENP activity in P. falciparum
soluble lysates and that inhibition of this protease alone is suffi-
cient to block parasite replication.
Althoughwe cannot rule out the possibility that VEA-260 inhibits
PfSENP2, we speculate that PfSENP2 may not be an active
protease.ThecatalyticdomainofPfSENP2hasundergoneasignif-
icant expansion relative to human SENPs, with nearly 200 addi-
tional amino acids relative to hSENP6 and 7, which themselves
contain a 200-amino acid insertion relative to hSENP1 and 2
(Table S1) (Lima and Reverter, 2008). Furthermore, the expansion
within PfSENP2 contains long stretches of amino acid repeat
sequences that may have disrupted protease function and may
have also prevented expression of PfSENP2 in E. coli. In addition,
PfSENP2homologs (yeastUlp2andhSENP6and7)primarily func-
tion in the processing of poly-SUMO chains (Kroetz et al., 2009;
Lima and Reverter, 2008). We demonstrated here that PfSUMO
cannot form poly-SUMO chains; therefore, it is unclear what role,
if any, PfSENP2 plays in SUMO regulation in the parasite.
Regardless of whether or not PfSENP2 is a functional
protease, VEA-260 is an inhibitor of PfSENP1. Most classes
of protease inhibitors that target cysteine proteases in
P. falciparum show some level of cross-reactivity with the falci-
pains (Arastu-Kapur et al., 2008; Greenbaum et al., 2002). Our
lead SENP inhibitor, VEA-260, did not cross-react with the other
major parasite cysteine proteases, including the falcipains, at
nearly double its EC50 value in the replication assay. Further-
more, JCP-668 showed dose-dependent inhibition of parasite
growth proportional to the decreased potency of this compound
for PfSENP1, and JCP-667 showed no toxicity to parasite
growth correlating with its inability to inhibit PfSENP1. Although
JCP-665 showed toxic effects not related to PfSENP1 inhibition,
these effects were not sufficient to fully block parasite replica-
tion. These data suggest that the complete block in parasite
replication by VEA-260 and JCP-668 was due to inhibition of
the target SENP. Modulation of PfSENP1 expression would be
useful to validate that VEA-260 susceptibility is proportional to
the level of PfSENP1. However, previous studies in yeast have
demonstrated that Ulp1 overexpression exerts a dominant-
negative effect and is therefore likely to result in lethality in
P. falciparum (Mossessova and Lima, 2000). Although VEA-260
also inhibits hSENP1 and 2, we demonstrated that it does not
inhibit all SENPs nor does it inhibit highly related cysteine prote-
ases, such as the DUB UCH-L3. These data indicate that
VEA-260 may be a promising lead compound with a high degree
of selectivity for PfSENP1 over other cysteine proteases.
Identification of a small molecule SENP-selective inhibitor also
provides a new tool for the analysis of the SUMOylation pathway
in P. falciparum. Recent proteomic analysis of SUMO modified
proteins inP. falciparum identified a preliminary list of 23 proteinsChemistry & Biology 18,(Issar et al., 2008). This is a surprisingly small number compared
to proteomic studies in other organisms including yeast (>200
proteins identified) and the highly related parasite Toxoplasma
gondii (>100 putative modified protein identified) (Braun et al.,
2009; Denison et al., 2005). For example, SUMOylation of PfSir2
was not observed by mass spectrometry in P. falciparum,
despite western blot and coimmunoprecipitation evidence that
this protein is in fact modified by SUMO. This is likely due
to the low levels of SUMO modified protein at any given time
and the high level of activity of SENPs in P. falciparum lysates.
With the discovery of small, cell permeable inhibitors of PfSENPs
it should be possible to generate more complete profiles of
SUMOylated proteins by mass spectrometry analysis. Further-
more, these inhibitors can be used to specifically block removal
of SUMO at specific stages of the parasite life cycle to provide
a more complete picture of the dynamics of SUMOylation.SIGNIFICANCE
SUMOylation is a dynamic process that is involved in the
regulation of a number of key biological processes. In
particular, SUMO modification is required for correct tran-
scriptional regulation. In the human parasite pathogen
Plasmodium falciparum, the causative agent of malaria,
a large percentage of genes are tightly regulated at the tran-
scriptional level during its 48 hr blood stage life cycle inside
the human host. However, very little is known about the
molecular mechanisms used by the parasite to control this
transcriptional program. Therefore, tools that will allow
a more detailed biochemical analysis of posttranslational
processes, such as SUMOylation, are likely to help shed light
on how the parasite regulates its blood stage processes. In
this study, we find that only one of two P. falciparum SENP
genes produce a functional enzyme. Biochemical studies
of this protease reveal that it has specificity for the parasite
SUMO-pro and some degree of unique specificity for
primary substrates compared to the human SENPs. To iden-
tify new classes of small molecule inhibitors of SENPs, we
screened a small focused library of protease inhibitors in
a newly developed assay in crude parasite extracts. This
screen identified a class of nonpeptidic aza-epoxides that
covalently inhibit the PfSENP1 protease. Using the lead
compound and various analogs with reduced potency for
PfSENP1, we were able to demonstrate that inhibition of
PfSENP1 correlates with parasite killing. Together, these
studies suggest that PfSENP1 may be a viable drug target
and provide valuable new tools for studying SUMOylation
in both parasites and other eukaryotic systems. These
studies should also enable future studies of the molecular
mechanisms of SUMOylation as it relates to the regulation
of the blood stage life cycle of this important human
pathogen.EXPERIMENTAL PROCEDURES
Sequence Alignment and Phylogram Generation of Predicted
P. falciparum SENPs
The catalytic domains of hSENPs 1, 2, 3, 5, 6, and 7, yeast Ulp1 and Ulp2, and
the predicted SENPs of P. falciparum, P. berghei, and P. yoelii were aligned711–721, June 24, 2011 ª2011 Elsevier Ltd All rights reserved 719
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Functional Studies of PfSENP1using ClustalW (MacVector 10.0.2). A phylogram was created based on this
alignment using the PhyML program with a bootstrapping procedure (number
of bootstraps = 100) available on Laboratoire d’Informatique, de Robotique et
deMicroe´lectronique (LIRM) atMontpellier (France) (http://www.phylogeny.fr).
Parasite Culture, Harvesting of Life Cycle Stages, and Lysate
Preparation
For details, see Supplemental Experimental Procedures.
Cloning and Expression of PfSUMO, Chimeric SUMOs, PfSENP1,
and PfSENP2
Strains, constructs, and primers for PfSUMO, chimeric SUMOs, PfSENP1, and
PfSENP2 are described in the Supplemental Experimental Procedures. All
constructs were expressed in BL21(DE3) E. coli (OD600 = 0.6; 0.1 mM IPTG)
for 3 hr at 30C, lysed in ML1B, and immobilized on Ni2+-NTA agarose. His6-
tagged PfSENP1 was eluted with imidazole whereas untagged PfSENP1
was eluted from the CPD fusion with 100 mM InsP6 (Lupardus et al., 2008).
PfSENP2 was not successfully expressed in either system.
SUMO-pro and SUMO-RanGAP1 Cleavage Assays
SUMO-pro and SUMO-RanGAP cleavage assays were performed as previ-
ously described (Mikolajczyk et al., 2007). For details see Supplemental Exper-
imental Procedures.
The SUMO-pro cleavage assay was modified to assess the effects of the
PfSUMOQ95T-pro mutation. PfSUMOQ95T-pro or PfSUMO-pro were incu-
bated with 2-fold serial dilutions of PfSENP1 or hSENP1 (400 nM–3.1 nM) for
1 hr at 37C. Proteins were separated by SDS-PAGE and visualized by
Gelcode Blue protein stain reagent (Pierce), and the protease concentration
required for 50% cleavage activity of the substrate (AC50) was estimated.
The SUMO-pro cleavage assay was also used to evaluate the reversibility of
VEA-260 and JCP-666. PfSENP1 (200 nM) was treated for 2 hr at 37C with
VEA-260 or JCP-666 (200 mM), NEM (10 mM), or DMSO in a final reaction
volume of 200 mL. An input sample was taken and then the inhibitor treated
protease was diluted, enriched with Ni2+-NTA, and eluted with 300 mM imid-
azole. The input and elution samples were subjected to the SUMO-pro pro-
cessing assay described above.
Positional Scanning Fluorogenic Substrate Library Screen
The fluorogenic substrate library screen was performed as described previ-
ously (Drag et al., 2008a, 2008b). Method details are provided in the Supple-
mental Experimental Procedures.
Cysteine Protease Inhibitor Library Screen
A library of 508 cysteine protease inhibitors was screened for inhibition of
PfSUMO-pro processing. For the screen, 1 ml of a 10mMDMSO stock solution
of each inhibitor (100 mM final concentration) was added to 10 mg of soluble
P. falciparum lysate in reaction buffer (50 mL reaction) and incubated for
30 min at room temperature in a 96-well plate format. The PfSUMO-pro
substrate was then added to the reaction (10 mM final concentration) and incu-
bated for 1 hr at 37C. PfSUMO-pro without lysate and lysate pretreated with
DMSO alone were used as positive and negative controls for inhibition on each
assay plate. The addition of 10 mL SDS loading dye quenched the reaction, and
cleavage was analyzed as described for the SUMO processing assays.
The lead compound JCP-666 was initially assessed by liquid chromatog-
raphy (Agilent 1100 Series)-mass spectrometry (API 150EX, Applied Bio-
systems) (LC-MS) (see Supplemental Compound Synthesis and Characteriza-
tion). However, the expected mass was not found. Subsequent chemical
analyses and re-synthesis of JCP-666 suggested that the epoxide of the reac-
tive warhead was unstable and modified by hydrochloric acid (see Supple-
mental Compound Synthesis and Characterization, Supplemental Results,
Scheme S1, and Scheme S2). VEA-260 was subsequently synthesized as
described in the Supplemental Compound Synthesis and Characterization.
The general scaffold of JCP-666 was used to perform a structure search of
the library to identify related analogs. The purity and identity of the analogs
JCP-665, JCP-667, and JCP-668 was assessed by LC-MS, HRMS, and
proton NMR (see Supplemental Compound Synthesis and Characterization).
Characterization of all compounds is described in detail in the Supplemental
Compound Characterization.720 Chemistry & Biology 18, 711–721, June 24, 2011 ª2011 ElsevierLabeling and Competition for Protease Activity with Activity-Based
Probes
The ability of VEA-260 to compete for labeling of common cysteine proteases
of P. falciparum was measured using two general activity-based probes as
described previously (Arastu-Kapur et al., 2008; Greenbaum et al., 2002)
and in more detail in the Supplemental Experimental Procedures.
SENP and DUB Fluorogenic Substrate Activity Assay
The ability of VEA-260 and JCP-666 to inhibit a panel of ubiquitin-like protein
deconjugating proteases, including PfSENP1, hSENP1, hSENP2, hSENP6,
hSENP8 (a deNEDDylase), UCHL3 (DUB), and IsoT (USP5; DUB), was tested
using a previously described fluorogenic substrate assay (Drag et al., 2008a,
2008b). See Supplemental Experimental Procedures for additional details.
P. falciparum Replication Assay
Synchronous P. falciparum ring-stage parasites (9 hr postinvasion; 1%
parasitemia; 0.5% hematocrit) were treated with VEA-260, JCP-666, JCP-
668, -665, or -667 at (0–300 mM) for 75 hr at 37C in a 96-well plate format. Cells
were fixed with 0.05% glutaraldehyde (Sigma) in phosphate-buffered saline
(PBS) overnight at 4C, permeabilized with 0.25% Triton X-100 for 5 min at
room temperature (25C), and stained with a 1:100 dilution of a 5 mg/ml
working solution of propidium iodide (Sigma) in 200 ml PBS. Parasite replica-
tion was monitored by observation of a propidium iodide-stained population
using a BD FACScan flow cytometer (Becton Dickinson) located in the Stan-
ford Shared FACS Facility at Stanford University. The data obtained were
analyzed to quantify the number of infected and uninfected red blood cells
using Flowjo 8.7.3. Parasitemia was determined as the ratio of infected cells
to total cells. Parasitemia was normalized to DMSO for each run. The assay
was repeated three to six times per drug per dose, and the EC50 was calcu-
lated by nonlinear regression using GraphPad Prizm software.
Susceptibility of the Different Life Cycle Stages to VEA260
Treatment
Synchronous parasites were treated for 12 hr with either DMSO or 100 mM of
VEA260 at late schizont (3 hr before rupture), ring (9 hr postinfection [p.i.]), late
ring (21 hr p.i.), or trophozoite (33 hr p.i.) stages. The morphology of the
VEA260-treated parasites was compared to that of the controls Giemsa-
stained thin blood smears.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
Supplemental Compound Synthesis and Characterization, Supplemental
Results, five figures, one table, two schemes and can be found with this article
online at doi:10.1016/j.chembiol.2011.04.010.
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